Cara Therapeutics Inc (NAS:CARA)

$ 0.2702 -0.0233 (-7.94%) Market Cap: 14.82 Mil Enterprise Value: -33.03 Mil PE Ratio: 0 PB Ratio: 1.39 GF Score: 31/100

Q4 2023 Cara Therapeutics Inc Earnings Call Transcript
Mar 04, 2024

$0.9998 (+5.24%)

Earnings
Cara Therapeutics Inc Corporate Update Call Transcript
Jan 22, 2024
Q3 2023 Cara Therapeutics Inc Earnings Call Transcript
Nov 13, 2023

$1.18 (+12.38%)

Earnings
Cara Therapeutics Inc at Canaccord Genuity Growth Conference Transcript
Aug 09, 2023
Q2 2023 Cara Therapeutics Inc Earnings Call Transcript
Aug 07, 2023

$2.95 (-5.75%)

Earnings
Cara Therapeutics Inc at Jefferies Healthcare Conference Transcript
Jun 08, 2023
Q1 2023 Cara Therapeutics Inc Earnings Call Transcript
May 15, 2023

$4.15 (+3.75%)

Earnings
Cara Therapeutics Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 17, 2023
Q4 2022 Cara Therapeutics Inc Earnings Call Transcript
Mar 06, 2023

$10.02 (-2.53%)

Earnings
Cara Therapeutics Inc Capital Markets Day Transcript
Feb 16, 2023
Cara Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 09, 2023
Cara Therapeutics Inc at Piper Sandler Healthcare Conference Transcript
Dec 01, 2022
Q3 2022 Cara Therapeutics Inc Earnings Call Transcript
Nov 07, 2022

$9.34 (+1.74%)

Earnings
Cara Therapeutics Inc Virtual NP Day Transcript
Sep 20, 2022
Q2 2022 Cara Therapeutics Inc Earnings Call Transcript
Aug 08, 2022

$11.5 (+2.04%)

Earnings
Cara Therapeutics Inc to Discuss KOMFORT Phase 2 Topline Data - Conference Call Transcript
Jun 30, 2022
Cara Therapeutics Inc at Bank of America Healthcare Conference Transcript
May 10, 2022
Q1 2022 Cara Therapeutics Inc Earnings Call Transcript
May 09, 2022

$7.45 (-7.34%)

Earnings
Cara Therapeutics Inc Research And Development Event (Virtual) Transcript
Mar 11, 2022
Q4 2021 Cara Therapeutics Inc Earnings Call Transcript
Mar 01, 2022

$10.06 (-2.99%)

Earnings
Cara Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 10, 2022
Q3 2021 Cara Therapeutics Inc Earnings Call Transcript
Nov 08, 2021

$17.23 (-3.69%)

Earnings
Cara Therapeutics Inc KORSUVA™ Injection Approval Conference Call Transcript
Aug 23, 2021
Q2 2021 Cara Therapeutics Inc Earnings Call Transcript
Aug 09, 2021

$12.51 (-2.11%)

Earnings
Cara Therapeutics Inc Annual Shareholders Meeting Transcript
Jun 03, 2021
Cara Therapeutics Inc at Jefferies Healthcare Conference (Virtual) Transcript
Jun 01, 2021
Cara Therapeutics Inc at Bank of America Global Research Healthcare Conference (Virtual) Transcript
May 13, 2021
Q1 2021 Cara Therapeutics Inc Earnings Call Transcript
May 10, 2021

$12.38 (-1.43%)

Earnings
Cara Therapeutics Inc Presenting Therapeutics KARE Phase 2 Topline Data -Corporate Call Transcript
Apr 29, 2021
Cara Therapeutics Inc R&D Day Transcript
Apr 07, 2021
Q4 2020 Cara Therapeutics Inc Earnings Call Transcript
Feb 25, 2021

$19.26 (-2.83%)

Earnings
Cara Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 13, 2021
Q3 2020 Cara Therapeutics Inc Earnings Call Transcript
Nov 09, 2020

$14.51 (+4.01%)

Earnings
Cara Therapeutics Inc to Discuss the US License Agreement for I.V. Korsuva with Vifor Pharma PLC Call Transcript
Oct 20, 2020
Q2 2020 Cara Therapeutics Inc Earnings Call Transcript
Aug 10, 2020

$17.22 (+1.59%)

Earnings
Cara Therapeutics Inc Annual Shareholders Meeting Transcript
Jun 04, 2020
Cara Therapeutics Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript
May 14, 2020
Q1 2020 Cara Therapeutics Inc Earnings Call Transcript
May 11, 2020

$15.78 (+11.36%)

Earnings
Cara Therapeutics, Inc. - Special Call Transcript
Apr 21, 2020
Q4 2019 Cara Therapeutics Inc Earnings Call Transcript
Feb 27, 2020

$15.35 (-3.22%)

Earnings
Cara Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 16, 2020
Cara Therapeutics, Inc. - Special Call Transcript
Dec 03, 2019
Q3 2019 Cara Therapeutics Inc Earnings Call Transcript
Nov 05, 2019

$20.74 (+1.77%)

Earnings
Q2 2019 Cara Therapeutics Inc Earnings Call Transcript
Aug 07, 2019

$22.63 (+1.85%)

Earnings
Cara Therapeutics, Inc. - KALM-1 Pivotal Phase 3 Trial of KORSUVA™ Injection in Hemodialysis Patients with Pruritus Call Transcript
May 29, 2019
Cara Therapeutics Inc at Bank of America Merrill Lynch Health Care Conference Transcript
May 16, 2019
Q1 2019 Cara Therapeutics Inc Earnings Call Transcript
May 07, 2019

$19 (-5.71%)

Earnings
Q4 2018 Cara Therapeutics Inc Earnings Call Transcript
Mar 12, 2019

$17.43 (+1.75%)

Earnings

Cara Therapeutics Inc Virtual NP Day Transcript

Sep 20, 2022 / 03:00PM GMT

Release Date Price: $9.75 (-0.91%)

Transcript

Iris Francesconi

Cara Therapeutics, Inc. - Chief Strategy Officer & Head of IR

Good morning, and welcome to Cara Therapeutics 2022 Virtual Notalgia Paresthetica event. Before we begin, let me remind you that today's presentation will include forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Please see Slide 2 of the accompanying presentation and our SEC filings for important risk factors that could cause our actual performance and results to differ materially from those expressed or implied in these forward-looking statements. We undertake no obligation to update or revise the information provided on this webinar as a result of new information or future results or developments.

Participating from Cara Therapeutics today will be Chris Posner, Cara's President and Chief Executive Officer; Dr. Joana Goncalves, Cara's Chief Medical Officer; and Eric Vandal, as VP of Commercial. We are delighted to also be joined by 2 highly accomplished key opinion leaders, Dr. Zoe Draelos and Dr. Brian Kim. Dr. Draelos is the Founder

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.